Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Up 588,312.5% in April

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 94,146 shares, an increase of 588,312.5% from the April 15th total of 16 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 591,063 shares, the short-interest ratio is currently 0.2 days.

Oncotelic Therapeutics Trading Up 5.9%

Shares of OTCMKTS:OTLC traded up $0.00 during trading on Monday, reaching $0.04. The stock had a trading volume of 1,408,932 shares, compared to its average volume of 284,886. The business has a fifty day moving average price of $0.04 and a 200-day moving average price of $0.07. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.01. The stock has a market cap of $17.52 million, a P/E ratio of 0.07 and a beta of -0.54. Oncotelic Therapeutics has a fifty-two week low of $0.02 and a fifty-two week high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last posted its quarterly earnings data on Wednesday, April 15th. The company reported $0.59 earnings per share for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.